Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre‐elafin (trappin‐2) expressed in Pichia pastoris
Open Access
- 4 June 2004
- journal article
- Published by Wiley in European Journal of Biochemistry
- Vol. 271 (12), 2370-2378
- https://doi.org/10.1111/j.1432-1033.2004.04156.x
Abstract
Elafin and its precursor, trappin-2 or pre-elafin, are specific endogenous inhibitors of human neutrophil elastase and proteinase 3 but not of cathepsin G. Both inhibitors belong, together with secretory leukocyte protease inhibitor, to the chelonianin family of canonical protease inhibitors of serine proteases. A cDNA coding either elafin or its precursor, trappin-2, was fused in frame with yeast alpha-factor cDNA and expressed in the Pichia pastoris yeast expression system. Full-length elafin or full-length trappin-2 were secreted into the culture medium with high yield, indicating correct processing of the fusion proteins by the yeast KEX2 signal peptidase. Both recombinant inhibitors were purified to homogeneity from concentrated culture medium by one-step cationic exchange chromatography and characterized by N-terminal amino acid sequencing, Western blot and kinetic studies. Both recombinant elafin and trappin-2 were found to be fast-acting inhibitors of pancreatic elastase, neutrophil elastase and proteinase 3 with k(ass) values of 2-4 x 10(6) m(-1).s(-1), while dissociation rate constants k(diss) were found to be in the 10(-4) s(-1) range, indicating low reversibility of the complexes. The equilibrium dissociation constant K(i) for the interaction of both recombinant inhibitors with their target enzymes was either directly measured for pancreatic elastase or calculated from k(ass) and k(diss) values for neutrophil elastase and proteinase 3. K(i) values were found to be in the 10(-10) molar range and virtually identical for both inhibitors. Based on the kinetic parameters determined here, it may be concluded that both recombinant elafin and trappin-2 may act as potent anti-inflammatory molecules and may be of therapeutic potential in the treatment of various inflammatory lung diseases.Keywords
This publication has 33 references indexed in Scilit:
- Production of Full-Length Human Pre-elafin, an Elastase Specific Inhibitor, from Yeast Requires the Absence of a Functional Yapsin 1 (Yps1p) EndoproteaseProtein Expression and Purification, 2000
- Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia.Journal of Clinical Investigation, 1996
- Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skinBiochemistry, 1993
- Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.Journal of Clinical Investigation, 1992
- Aerosol α1 -antitrypsin treatment for cystic fibrosisThe Lancet, 1991
- Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.Journal of Clinical Investigation, 1991
- Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDaAnalytical Biochemistry, 1987
- In vivo significance of kinetic constants of protein proteinase inhibitorsBiochemical Medicine, 1984
- The synthesis and analytical use of a highly sensitive and convenient substrate of elastaseBiochemical Medicine, 1974
- [7] ElastaseMethods in Enzymology, 1970